Discovery of selective small-molecule CD80 inhibitors

Journal of Biomolecular Screening

Volumn 12, Issue 4, 2007, Pages 464-472

  Uvebrant, Kristina ^a,b   Da Graça Thrige, Dorthe ^a   Rosén, Anna ^c   Åkesson, Mats ^d   Berg, Helena ^e   Walse, Björn ^f   Björk, Per ^a  

^a Active Biotech Research AB   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Alligator Bioscience AB   (Sweden)

^d Wieslab AB   (Sweden)

^e Acadia Pharmaceuticals AB   (Sweden)

^f SARomics AB   (Sweden)

Author keywords

Costimulation; Drug discovery; Inhibitors; Protein protein interaction; Screening assay

Indexed keywords

B7 ANTIGEN; B7 INHIBITOR; BLOCKING AGENT; CD28 ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BIOSENSOR; CONTROLLED STUDY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; FEMALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SCINTISCANNING; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIGENS, CD80; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DESIGN; GOATS; HUMANS; MICE; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; RABBITS;

EID: 34249909243     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057107300464     Document Type: Article

References (32)

1. Drews J.: Drug discovery: a historical perspective. Science 2000 ; 287: 1960-1964.
2. Arkin MR, Wells JA: Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 2004 ; 3: 301-317.
3. Dick AD, Isaacs JD: Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium. Br J Ophthalmol 1999 ; 83: 1230-1234.
4. Marshall SA, Lazar GA, Chirino AJ, Desjarlais JR: Rational design and engineering of therapeutic proteins. Drug Discov Today 2003 ; 8: 212-221.
5. Cavagnaro JA: Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nat Rev Drug Discov 2002 ; 1: 469-475.
6. Clackson T., Wells JA: A hot spot of binding energy in a hormone-receptor interface. Science 1995 ; 267: 383-386.
7. DeLano WL: Unraveling hot spots in binding interfaces: progress and challenges. Curr Opin Struct Biol 2002 ; 12: 14-20.
8. Carreno BM, Collins M.: The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002 ; 20: 29-53.
9. Lenschow DJ, Walunas TL, Bluestone JA: CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996 ; 14: 233-258.
10. Salomon B., Bluestone JA: Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001 ; 19: 225-252.
11. Kobata T., Azuma M., Yagita H., Okumura K.: Role of costimulatory molecules in autoimmunity. Rev Immunogenet 2000 ; 2: 74-80.
12. Windhagen A., Newcombe J., Dangond F., Strand C., Woodroofe MN, Cuzner ML,, et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995 ; 182: 1985-1996.
13. Ranheim EA, Kipps TJ: Elevated expression of CD80 (B7/BB1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis. Arthritis Rheum 1994 ; 37: 1637-1646.
14. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA,, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995 ; 80: 707-718.
15. Lenschow DJ, Ho SC, Sattar H., Rhee L., Gray G., Nabavi N.,, et al. Differential effects of anti-B7-1 and anti B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995 ; 181: 1145-1155.
16. Chang TT, Sobel RA, Wei T., Ransohoff RM, Kuchroo VK, Sharpe AH: Recovery from EAE is associated with decreased survival of encephalitogenic T cells in the CNS of B7-1/B7-2-dificient mice. Eur J Immunol 2003 ; 33: 2022-2032.
17. Garber K.: Make a break for costimulatory blockers. Nat Biotechnol 2004 ; 22: 145-147.
18. Davis SJ, Ikemizu S., Wild MK, van der Merwe PA: CD2 and the nature of protein interactions mediating cell-cell recognition. Immunol Rev 1998 ; 163: 217-236.
19. Sørensen P., Kussmann M., Rosén A., Bennett KL, da Graça Thrige D., Uvebrant K.,, et al. Identification of protein-protein interfaces implicated in CD80-CD28 costimulatory signaling. J Immunol 2004 ; 172: 6803-6809.
20. Olsson C., Michaelsson E., Parra E., Pettersson U., Lando PA, Dohlsten M.: Biased dependency of CD80 versus CD86 in the induction of transcription factors regulating the human IL-2 promotor. Int Immunol 1998 ; 10: 499-506.
21. Mellor GW, Burden MN, Preudat M., Joseph Y., Cooksley SB, Ellis JH,, et al. Development of a CD28/CD86 (B7-2) binding assay for high throughput screening by homogeneous time-resolved fluorescence. J Biomol Screen 1998: 3 ; 91-99.
22. Karlsson R., Kullman-Magnusson M., Hamalainen MD, Remaeus A., Andersson K., Borg P.,, et al. Biosensor analysis of drug-target interactions: direct and competitive binding assays for investigation of interactions between thrombin and thrombin inhibitors. Anal Biochem 2000 ; 278: 1-13.
23. Dustin ML: The immunological synapse. Arthritis Res 2002 ; 4 (suppl 3). 119-125.
24. Björk P., Fex T., Pettersson Log, Sørensen P., da Graça Thrige D.: Novel immunomodulating compounds. January 16, 2003. Active Biotech AB, Sweden. PCT Int. Appl. WO 03004495.
25. Wetzel SA, McKeithan TW, Parker DC: Live-cell dynamics and the role of costimulation in immunological synapse formation. J Immunol 2002 ; 169: 6092-6101.
26. Bromley SK, Burack WR, Johnson KG, Somersalo K., Sims TN, Sumen C.,, et al. The immunological synapse. Annu Rev Immunol 2001 ; 19: 375-396.
27. Huxley P., Sutton DH, Debnam P., Matthews IR, Brewer JE, Rose J.,, et al. High-affinity small molecule inhibitors of T cell costimulation: compounds for immunotherapy. Chem Biol 2004 ; 11: 1651-1658.
28. Erbe DV, Wang S., Xing Y., Tobin JF: Small molecule ligands define a binding site on the immune regulatory protein B7.1. J Biol Chem 2002 ; 277: 7363-7368.
29. Stamper CC, Zhang Y., Tobin JF, Erbe DV, Ikemizu S., Davis SJ,, et al. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 2001 ; 410: 608-611.
30. Evans EJ, Esnouf RM, Manson-Sancho R., Gilbert RJ, James JR, Yu C.,, et al. Crystal structure of a soluble CD28-Fab complex. Nat Immunol 2006 ; 6: 271-279.
31. Schwartz JC, Zhang X., Fedorov AA, Nathenson SG, Almo SC: Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature 2001 ; 410: 604-608.
32. Aruffo A., Hollenbaugh D.: Therapeutic intervention with inhibitors of costimulatory pathways in autoimmune disease. Curr Opin Immunol 2001 ; 13: 683-686.